To study JAK inhibitor Tofacitinib effect on pain and signs of central sensitization (CS) in patients with active Rheumatoid Arthritis (7-28 days) after the start of therapy
Latest Information Update: 30 Jun 2020
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 30 Jun 2020 New trial record
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism